NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced upcoming presentations at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI), from June 22 ? 26, 2018 in Anaheim, Ca. Presentation topics encompass ongoing domestic Mo-99 production, expansion plans and use of the RadioGenix® System (technetium 99m generator). Details of the presentations by NorthStar are listed below.
Sunday, June 23, 2019 |
|||
Session Title: | TS06: Radiopharmacy/Radiation Safety 1 | ||
Presentation Title: |
Mo-99 Supply Update ? the RadioGenix System and Tc-99m Production Using Non-uranium Based, Domestic Mo-99 |
||
Presenter: | David V. Wilson, BS, RPh | ||
Session Time: | 3:00 ? 4:30 PM PT | ||
Presentation Time: | 3:45 ? 4:30 PM PT | ||
Location: | Room 206B | ||
Monday, June 24, 2019 |
|||
Session Title: | CORAR Session: Industry Outlook on Current and Future Mo-99 Supply | ||
Presentation Title: |
NorthStar Medical Technologies Update |
||
Presenter: | James Harvey, PhD | ||
Session Time: | 12:30 ? 2:00 PM PT | ||
Presentation Time: | 12:50 ? 12:55 PM PT | ||
Location: | Room 210D | ||
NorthStar Medical Radioisotopes invites participants at this year's SNMMI Annual Meeting to attend the presentations above and to visit the company at Exhibit Booth 957.
About the RadioGenix® System
The
RadioGenix System is an innovative, high tech separation platform that
is approved for processing non-uranium/non-highly enriched uranium based
molybdenum-99 (Mo-99) for the production of the important medical
radioisotope, technetium-99m (Tc-99m). Prior to availability of
RadioGenix technology, the U.S. supply chain for Mo-99 has been subject
to frequent and sometimes severe interruptions which negatively impact
patient healthcare. Approved by the U.S. Food and Drug Administration in
2018, the RadioGenix System is the first and only on-site, automated
isotope separation system of its kind for use with
non-uranium/non-highly enriched uranium based Mo-99, designed to help
alleviate shortage situations and expand domestic supply.
Indication and Important Risk Information About the RadioGenix® System and Sodium Pertechnetate Tc 99m Injection USP
The RadioGenix System is a technetium Tc-99m generator used to produce Sodium Pertechnetate Tc 99m Injection, USP. Sodium Pertechnetate Tc 99m Injection is a radioactive diagnostic agent and can be used in the preparation of FDA-approved diagnostic radiopharmaceuticals.
Sodium Pertechnetate Tc 99m Injection is also indicated in
IMPORTANT RISK INFORMATION
To report SUSPECTED ADVERSE REACTIONS, contact NorthStar Medical Radioisotopes, LLC at 1-844-438-6659; or FDA at 1-800-332-1088 or www.fda.gov/medwatch.
For Full RadioGenix® System Prescribing Information, click here or visit https://www.northstarnm.com/wp-content/uploads/2018/04/PI_Rev04_23mar2018.pdf.
About NorthStar Medical Radioisotopes, LLC (NorthStar)
NorthStar
Medical Radioisotopes is a nuclear medicine technology company committed
to providing the United States with reliable and environmentally
friendly radioisotope supply solutions to meet the needs of patients and
to advance clinical research. The Company's first product is the
RadioGenix® System, an innovative and flexible platform
technology initially approved by the U.S. Food and Drug Administration
in 2018 for the processing of non-uranium/non-highly enriched uranium
based molybdenum-99 (Mo-99), the parent isotope of technetium-99m
(Tc-99m), which is currently the most widely used diagnostic
radioisotope for medical purposes. NorthStar's proprietary and patented
technologies include non-uranium based molybdenum-99 domestic production
methods, patented separation chemistry systems, patented sterilization
systems and a technology platform that potentially allows expanded
product offerings to provide solutions in both the diagnostic and
therapeutic markets. Founded in 2006 and based in Beloit, Wis.,
NorthStar Medical Radioisotopes, LLC is a wholly-owned subsidiary of
NorthStar Medical Technologies, LLC. For more information, visit: www.northstarnm.com.
These press releases may also interest you
|